Drug Profile
MEDI 7836
Alternative Names: Anti-IL-13 MAb-YTE; MEDI7836Latest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator MedImmune
- Class
- Mechanism of Action Interleukin 13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 12 Sep 2016 Discontinued - Phase-I for Asthma (In volunteers) in United Kingdom (SC)
- 30 Apr 2016 MedImmune completes a phase I trial in Asthma (In volunteers) in the UK (NCT02388347)
- 01 Mar 2015 Phase-I clinical trials in Asthma (In volunteers) in United Kingdom (SC)